CD109 (CD109 molecule)
Written | 2011-08 | Shinji Mii, Yoshiki Murakumo, Masahide Takahashi |
Department of Pathology, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan |
(Note : for Links provided by Atlas : click)
1. Identity
Alias_names | General Information |
Alias_symbol (synonym) | FLJ38569 |
DKFZp762L1111 | |
CPAMD7 | |
Other alias | FLJ41966 |
RP11-525G3.1 | |
HGNC (Hugo) | CD109 |
LocusID (NCBI) | 135228 |
Atlas_Id | 42925 |
Location | 6q13 [Link to chromosome band 6q13] |
Location_base_pair | Starts at 73696085 and ends at 73828317 bp from pter ( according to hg19-Feb_2009) [Mapping CD109.png] |
Fusion genes (updated 2017) | Data from Atlas, Mitelman, Cosmic Fusion, Fusion Cancer, TCGA fusion databases with official HUGO symbols (see references in chromosomal bands) |
CD109 (6q13) / CELF1 (11p11.2) | CD109 (6q13) / MTO1 (6q13) | CD109 (6q13) / NPHP1 (2q13) | |
DPP4 (2q24.2) / CD109 (6q13) |
Note | CD109 is a glycosylphosphatidylinositol (GPI)-anchored cell-surface glycoprotein and is a member of the alpha-2-macroglobulin/C3,C4,C5 family of thioester-containing proteins. |
2. DNA/RNA
![]() | |
Exon-intron structure of CD109 gene. The vertical bars correspond to exons. | |
Description | CD109 is a gene of 132.53 kb comprising 33 exons and 32 introns. The 5' part of exon 1 and the 3' part of exon 33 are non-coding. |
Transcription | Three splice variants are known. The length of the longest variant is 9464 bp (CDS: 426-4763). mRNA is mainly expressed in skin and testis. |
Pseudogene | Not known. |
3. Protein
![]() | |
Representation of the CD109 protein with localization of recognized domains. CD109 protein is a GPI-anchored protein having signal peptide, Gov antigen, thioester region, and furinase cleavage site. | |
Description | CD109 is a GPI-anchored cell-surface glycoprotein and is a member of the alpha-2-macroglobulin/C3,C4,C5 family of thioester-containing proteins (Sutherland et al., 1991; Haregewoin et al., 1994; Smith et al., 1995; Lin et al., 2002). The CD109 protein was first identified as a cell-surface antigen detected by a monoclonal antibody raised against the primitive lymphoid/myeloid cell line KG1a (Sutherland et al., 1991). It was also shown that CD109 carries the biallelic platelet-specific alloantigen Gov (Kelton et al., 1990; Smith et al., 1995). |
Expression | CD109 is expressed on a subset of fetal and adult CD34+ bone marrow mononuclear cells, mesenchymal stem cell subsets, phytohemagglutinin (PHA)-activated T lymphoblasts, thrombin-activated platelets, leukemic megakaryoblasts, endothelial cells, and some human tumor cell lines, but not on fresh peripheral leukocytes and normal bone marrow leukocytes (Kelton et al., 1990; Murray et al., 1999; Giesert et al., 2003). In normal human tissues other than hematopoietic cells, CD109 is expressed in limited cells including the myoepithelial cells of the mammary, lacrimal, salivary and bronchial glands and the basal cells of the prostate and the bronchial epithelia (Hashimoto et al., 2004; Zhang et al., 2005; Sato et al., 2007; Hasegawa et al., 2007; Hasegawa et al., 2008). Recently, it has been reported that CD109 is highly expressed in several types of human cancer tissues, in particular squamous cell carcinomas (Hashimoto et al., 2004; Zhang et al., 2005; Sato et al., 2007; Hasegawa et al., 2007; Hasegawa et al., 2008; Järvinen et al., 2008; Hagiwara et al., 2008; Ohshima et al., 2010; Hagikura et al., 2010). |
Localisation | Plasma membrane. |
Function | CD109 negatively regulates TGF-beta signaling in keratinocytes by directly modulating TGF-beta receptor activity in vitro (Finnson et al., 2006). |
Homology | Orthologs: mouse CD109, rat CD109, cow CD109, dog CD109, chicken CD109, hagfish CD109, nematode CD109. Paralogs: alpha-2-macroglobulin, alpha-2-macroglobulin-like-1, C3, C4, C5, PZP, CPAMD8. |
4. Mutations
Note | A Tyr703Ser polymorphism of CD109 is associated with Gova and Govb alloantigenic determination (Schuh et al., 2002). |
5. Implicated in
Note | |
Entity | Various cancer |
Note | CD109 is upregulated in squamous cell carcinomas (SCCs) of lung, esophagus, uterus and oral cavity, malignant melanoma of skin, and urothelial carcinoma of urinary bladder (Hashimoto et al., 2004; Zhang et al., 2005; Sato et al., 2007; Hasegawa et al., 2007; Hasegawa et al., 2008; Järvinen et al., 2008; Hagiwara et al., 2008; Ohshima et al., 2010; Hagikura et al., 2010). |
Prognosis | The CD109 expression is significantly higher in well-differentiated SCCs of the oral cavity and in low-grade urothelial carcinomas of the urinary bladder than in moderately- or poorly-differentiated SCCs and in high-grade urothelial carcinomas, respectively (Hagiwara et al., 2008; Hagikura et al., 2010). |
Entity | Alloimmune thrombocytopenic syndromes |
Note | Refractoriness to platelet transfusion, post-transfusion purpura, and neonatal alloimmune thrombocytopenia (Smith et al., 1995). |
Disease | These diseases are included in alloimmune thrombocytopenic syndromes. Gova/b platelet alloantigens, which reside in the CD109 protein, are the cause of these 3 diseases. |
6. Bibliography
Identification of CD109 as part of the TGF-beta receptor system in human keratinocytes. |
Finnson KW, Tam BY, Liu K, Marcoux A, Lepage P, Roy S, Bizet AA, Philip A. |
FASEB J. 2006 Jul;20(9):1525-7. Epub 2006 Jun 5. |
PMID 16754747 |
Antibody W7C5 defines a CD109 epitope expressed on CD34+ and CD34- hematopoietic and mesenchymal stem cell subsets. |
Giesert C, Marxer A, Sutherland DR, Schuh AC, Kanz L, Buhring HJ. |
Ann N Y Acad Sci. 2003 May;996:227-30. |
PMID 12799300 |
Correlation of pathological grade and tumor stage of urothelial carcinomas with CD109 expression. |
Hagikura M, Murakumo Y, Hasegawa M, Jijiwa M, Hagiwara S, Mii S, Hagikura S, Matsukawa Y, Yoshino Y, Hattori R, Wakai K, Nakamura S, Gotoh M, Takahashi M. |
Pathol Int. 2010 Nov;60(11):735-43. doi: 10.1111/j.1440-1827.2010.02592.x. Epub 2010 Oct 6. |
PMID 20946523 |
Up-regulation of CD109 expression is associated with carcinogenesis of the squamous epithelium of the oral cavity. |
Hagiwara S, Murakumo Y, Sato T, Shigetomi T, Mitsudo K, Tohnai I, Ueda M, Takahashi M. |
Cancer Sci. 2008 Oct;99(10):1916-23. |
PMID 19016750 |
Cellular expression of a GPI-linked T cell activation protein. |
Haregewoin A, Solomon K, Hom RC, Soman G, Bergelson JM, Bhan AK, Finberg RW. |
Cell Immunol. 1994 Jul;156(2):357-70. |
PMID 8025953 |
CD109 expression in basal-like breast carcinoma. |
Hasegawa M, Moritani S, Murakumo Y, Sato T, Hagiwara S, Suzuki C, Mii S, Jijiwa M, Enomoto A, Asai N, Ichihara S, Takahashi M. |
Pathol Int. 2008 May;58(5):288-94. |
PMID 18429827 |
Expression of CD109 in human cancer. |
Hashimoto M, Ichihara M, Watanabe T, Kawai K, Koshikawa K, Yuasa N, Takahashi T, Yatabe Y, Murakumo Y, Zhang JM, Nimura Y, Takahashi M. |
Oncogene. 2004 Apr 29;23(20):3716-20. |
PMID 15116102 |
High-resolution copy number and gene expression microarray analyses of head and neck squamous cell carcinoma cell lines of tongue and larynx. |
Jarvinen AK, Autio R, Kilpinen S, Saarela M, Leivo I, Grenman R, Makitie AA, Monni O. |
Genes Chromosomes Cancer. 2008 Jun;47(6):500-9. |
PMID 18314910 |
Gova/b alloantigen system on human platelets. |
Kelton JG, Smith JW, Horsewood P, Humbert JR, Hayward CP, Warkentin TE. |
Blood. 1990 Jun 1;75(11):2172-6. |
PMID 2346781 |
Cell surface antigen CD109 is a novel member of the alpha(2) macroglobulin/C3, C4, C5 family of thioester-containing proteins. |
Lin M, Sutherland DR, Horsfall W, Totty N, Yeo E, Nayar R, Wu XF, Schuh AC. |
Blood. 2002 Mar 1;99(5):1683-91. |
PMID 11861284 |
CD109 is expressed on a subpopulation of CD34+ cells enriched in hematopoietic stem and progenitor cells. |
Murray LJ, Bruno E, Uchida N, Hoffman R, Nayar R, Yeo EL, Schuh AC, Sutherland DR. |
Exp Hematol. 1999 Aug;27(8):1282-94. |
PMID 10428505 |
CD109 expression levels in malignant melanoma. |
Ohshima Y, Yajima I, Kumasaka MY, Yanagishita T, Watanabe D, Takahashi M, Inoue Y, Ihn H, Matsumoto Y, Kato M. |
J Dermatol Sci. 2010 Feb;57(2):140-2. Epub 2010 Jan 7. |
PMID 20034764 |
High-level expression of CD109 is frequently detected in lung squamous cell carcinomas. |
Sato T, Murakumo Y, Hagiwara S, Jijiwa M, Suzuki C, Yatabe Y, Takahashi M. |
Pathol Int. 2007 Nov;57(11):719-24. |
PMID 17922683 |
A tyrosine703serine polymorphism of CD109 defines the Gov platelet alloantigens. |
Schuh AC, Watkins NA, Nguyen Q, Harmer NJ, Lin M, Prosper JY, Campbell K, Sutherland DR, Metcalfe P, Horsfall W, Ouwehand WH. |
Blood. 2002 Mar 1;99(5):1692-8. |
PMID 11861285 |
Characterization and localization of the Gova/b alloantigens to the glycosylphosphatidylinositol-anchored protein CDw109 on human platelets. |
Smith JW, Hayward CP, Horsewood P, Warkentin TE, Denomme GA, Kelton JG. |
Blood. 1995 Oct 1;86(7):2807-14. |
PMID 7670116 |
Identification of a cell-surface antigen associated with activated T lymphoblasts and activated platelets. |
Sutherland DR, Yeo E, Ryan A, Mills GB, Bailey D, Baker MA. |
Blood. 1991 Jan 1;77(1):84-93. |
PMID 1984805 |
CD109 expression in squamous cell carcinoma of the uterine cervix. |
Zhang JM, Hashimoto M, Kawai K, Murakumo Y, Sato T, Ichihara M, Nakamura S, Takahashi M. |
Pathol Int. 2005 Apr;55(4):165-9. |
PMID 15826242 |
7. Citation
This paper should be referenced as such : |
Mii, S ; Murakumo, Y ; Takahashi, M |
CD109 (CD109 molecule) |
Atlas Genet Cytogenet Oncol Haematol. 2012;16(1):34-36. |
Free journal version : [ pdf ] [ DOI ] |
On line version : http://atlasgeneticsoncology.usal.es/classic/Genes/CD109ID42925ch6q13.html |
8. External links
REVIEW articles | automatic search in PubMed |
Last year publications | automatic search in PubMed |
© Atlas of Genetics and Cytogenetics in Oncology and Haematology | indexed on : Thu Jan 17 18:50:51 CET 2019 |
For comments and suggestions or contributions, please contact us atlasgeneticsoncology@usal.es.